Spinal Cord Injuries
Conditions
Brief summary
This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability and motor function in individuals with spinal cord injuries of differing chronicity and severity. Participants will visit the lab on 4 separate occasions where they will be administered four different drugs in a randomized, double-blinded, placebo-controlled crossover design.
Detailed description
This study will assess for the first time the effects of 5-HTP on neural excitability utilizing a combination of neurophysiological and functional testing in subacute motor complete (AIS A/B), chronic motor complete (AIS A/B) and chronic incomplete (AIS C/D) SCI participants. To reduce peripheral side effects such as nausea, these supplements will be co-administered with carbidopa which inhibits the action of peripheral AADC, thereby ensuring that 5-HTP can effectively cross the blood brain barrier prior to being broken down. The neurophysiological outcomes will allow for the determination of the mechanistic actions of each pharmacological agent on different pathways/sites within the central nervous system in three different patient populations with varying degrees of lesion severity and will for the determination of whether increased Amino Acid Decarboxylase (AADC) expression and therefore the efficacy of this approach is correlated to lesion severity and/or chronicity. Importantly, the use of functional testing will allow for the determination of whether these often-reported neurophysiological changes translate to improvements in muscle activation patterns and kinematics during cycling. The effects of 5-HTP will be assessed across three different participant groups: i) subacute (6 months-1 year) AIS A/B SCI individuals, ii) chronic (\>2 years post injury) AIS A/B SCI individuals and iii) chronic AIS C/D SCI individuals.. In a placebo-controlled, randomized crossover design, participants will receive i) 50 mg 5HTP combined with 50 mg carbidopa, ii) 100 mg 5-HTP combined with 50 mg carbidopa, iii) 50 mg carbidopa only or iv) placebo. Ten participants will be recruited in each group. Participants will visit the lab on four separate occasions, separated by at least 72 hours.
Interventions
100mg combined with 50mg carbidopa
50mg combined with 50mg carbidopa
DRUGCarbidopa
50mg
DRUGPlacebo
Placebo
Sponsors
University of Alberta
Wings for Life
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* participants must have suffered trauma to the spinal cord at least six months ago or longer
Exclusion criteria
* individuals with damage to the nervous system other than to the spinal cord * pregnant and/or breastfeeding women * alcoholic participants * history of seizure/epilepsy * history of suicidal thoughts or behaviors * known or suspected allergy to the medication ingredients * cardiovascular disease including history of heart attack or heart rhythm irregularities * coronary artery disease * reduced liver function or disease * reduced kidney function or disease * lung disease * comatose or depressed states due to CNS depressants * endocrine dysfunction * blood dyscrasias or blood related disease * bone marrow depression * hypocalcemia * history of stomach ulcers * wide angle glaucoma * phenylketonuria * history of tumors * uncontrolled heart problems * unstable psychiatric or mental disorder Participants taking: * monoamine oxidase inhibitor therapy * serotonergic antidepressants * tricyclic antidepressants * any type of serotonergic agonist * dopamine D2 receptor antagonists * amphetamine * CNS depressants * levodopa * lithium * anti-hypertensive drugs * iron salts * metoclopramide * phenothiazine medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in motoneuron excitability | Pre drug-intake, 30minutes, 60minutes, 90minutes and 120minutes post drug-intake | F waves |
| Change in spinal excitability | Pre drug-intake, 30minutes, 60minutes, 90minutes and 120minutes post drug-intake | H reflex |
| Change in flexor reflex/spasms | Pre drug-intake, 30minutes, 60minutes, 90minutes and 120minutes post drug-intake | Cutaneomuscular reflex |
| Change in functional movement performance | Pre drug-intake, 120-150minutes post drug-intake | Leg cycling task |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum analysis of 5HIAA (UofL Cohort only) | 90-120minutes post drug-intake | 5-HIAA (serum) |
| Serum analysis of serotonin (UofL Cohort only) | 90-120minutes post drug-intake | 5-HT (serum and whole blood), cortisol |
| Serum analysis of cortisol (UofL Cohort only) | 90-120minutes post drug-intake | serum cortisol |
| Whole blood analysis of Serotonin (UofL Cohort only) | 90-120minutes post drug-intake | Blood 5HT |
Countries
Canada, United States
Contacts
PRINCIPAL_INVESTIGATORJessica D'Amico, PhD
University of Alberta
Outcome results
None listed